Prestige Consumer Healthcare reports FY2026 results, announces $150M LaCorium acquisition

Filed May 13, 2026 · Period ending May 13, 2026 · ~2 min read

Key Changes

• high

  Prestige agreed to acquire LaCorium Health, an Australian therapeutic skin-care leader, for ~$150M cash. LaCorium generated ~$40M in trailing twelve-month revenue and is expected to produce ~$12M in EBITDA including synergies. Close expected Q2 FY2027.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  FY2026 revenue fell 4.3% to $1,089M, driven by limited supply of Clear Eyes eye care products due to production volatility at the acquired Pillar5 facility. Adjusted diluted EPS declined to $4.38 from $4.52 prior year. Free cash flow rose to $246.4M.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• high

  FY2027 guidance: revenue $1,100M–$1,121M (organic growth 1%–3%), adjusted diluted EPS $4.42–$4.51, free cash flow $250M+. Guidance excludes pending LaCorium and Breathe Right acquisitions, both expected to close June–July 2026.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →